Several studies showed that p-STAT3 is over-expressed in the majority of GBM patients and associated with mesenchymal differentiation and worse prognosis in gliomas [38], making the STAT3 signaling pathway an important therapeutic target for glioma treatment [39,40]. Here, STAT3 is linked to central nervous system cancer.